BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36938639)

  • 1. Fibroblast growth factor receptors 1 and 4 combined with lymph node metastasis predicts poor prognosis in oral cancer.
    Gu ZY; Zhou R; Hong D; Han Y; Wang LZ; Li J; Zhang ZY; Shi CJ
    Oral Dis; 2024 Apr; 30(3):1004-1017. PubMed ID: 36938639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
    Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
    Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
    EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
    Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
    J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas.
    Fisher MM; SenthilKumar G; Hu R; Goldstein S; Ong IM; Miller MC; Brennan SR; Kaushik S; Abel L; Nickel KP; Iyer G; Harari PM; Kimple RJ; Baschnagel AM
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):793-803. PubMed ID: 32298810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
    Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
    Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.
    Tucker JA; Klein T; Breed J; Breeze AL; Overman R; Phillips C; Norman RA
    Structure; 2014 Dec; 22(12):1764-1774. PubMed ID: 25465127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
    Vlacic G; Hoda MA; Klikovits T; Sinn K; Gschwandtner E; Mohorcic K; Schelch K; Pirker C; Peter-Vörösmarty B; Brankovic J; Dome B; Laszlo V; Cufer T; Rozman A; Klepetko W; Grasl-Kraupp B; Hegedus B; Berger W; Kern I; Grusch M
    Cells; 2019 Sep; 8(9):. PubMed ID: 31527449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib.
    Luo H; Quan J; Xiao H; Luo J; Zhang Q; Pi G; Ye Y; He R; Liu Y; Su X; Zhao L; Wang G
    Oncol Rep; 2018 May; 39(5):2270-2278. PubMed ID: 29517107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer.
    SenthilKumar G; Fisher MM; Skiba JH; Miller MC; Brennan SR; Kaushik S; Bradley ST; Longhurst CA; Buehler D; Nickel KP; Iyer G; Kimple RJ; Baschnagel AM
    Mol Cancer Ther; 2020 Jun; 19(6):1255-1265. PubMed ID: 32371583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
    Paik PK; Shen R; Berger MF; Ferry D; Soria JC; Mathewson A; Rooney C; Smith NR; Cullberg M; Kilgour E; Landers D; Frewer P; Brooks N; André F
    Clin Cancer Res; 2017 Sep; 23(18):5366-5373. PubMed ID: 28615371
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclo-oxygenase-2 expression is associated with vascular endothelial growth factor C expression and lymph node metastasis in oral squamous cell carcinoma.
    Kono M; Watanabe M; Abukawa H; Hasegawa O; Satomi T; Chikazu D
    J Oral Maxillofac Surg; 2013 Oct; 71(10):1694-702. PubMed ID: 23809761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
    Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
    Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
    Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
    Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
    Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients.
    Choi CH; Chung JY; Kim JH; Kim BG; Hewitt SM
    J Transl Med; 2016 May; 14(1):124. PubMed ID: 27154171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
    Khandelwal AR; Kent B; Hillary S; Alam MM; Ma X; Gu X; DiGiovanni J; Nathan CO
    Mol Carcinog; 2019 Oct; 58(10):1715-1725. PubMed ID: 31254372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer.
    Inokuchi M; Murase H; Otsuki S; Kawano T; Kojima K
    World J Surg Oncol; 2017 Jan; 15(1):2. PubMed ID: 28056982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.